Methods for treating diabetes, hepatitis, and/or inflammatory liver disease
AssigneesUniversity of Connecticut, Joslin Diabetes Center, Inc.
InventorsMichael A. LYNES, Yu-Hua TSENG, Matthew D. LYNES
Life of this patent
Estimating the term…
Abstract
Disclosed herein are uses of inhibitor of extracellular human metallothionein (MT) to treat a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, and compositions containing extracellular human MT.
Claims19
A method for treating or limiting development of a disorder selected from the group consisting of diabetes, pre-diabetes, impaired glucose tolerance, hepatitis, and/or inflammatory liver disease, comprising administering to a subject with the disorder or at risk of the disorder a therapeutically effective amount of a composition comprising an inhibitor of extracellular human metallothionein (MT) to treat or limit development of the disorder.
2-28. (canceled)
A composition, comprising:
- (a) an inhibitor of extracellular human metallothionein (MT);
- and
- (b) a pancreatic or hepatic cell targeting moiety linked to the inhibitor of extracellular human MT.
A composition, comprising
- (a) an inhibitor of extracellular human metallothionein (MT);
- and
- (b) one or more of insulin, metformin, pramlintide, a sulfonylurea (including but not limited to glyburide, glipizide, and glimepiride), a meglitinide (including but not limited to repaglinide and nateglinide), a thiazolidinedione (including but not limited to rosiglitazone and pioglitazone), a DPP-4 inhibitor (including but not limited to sitagliptin, saxagliptin, and linagliptin), a GLP-1 receptor agonist (including but not limited to exenatide, liraglutide, and semaglutide), a SGLT2 inhibitor (including but not limited to canagliflozin, dapagliflozin, and empagliflozin), entecavir, tenofovir, lamivudine, adefovir, telbivudine, simeprevir, sofosbuvir, interferon or ribavirin.
(canceled)
Dependencies are inferred from the claim text.